Annalisa Nuccitelli

Annalisa Nuccitelli has a diverse work experience in the field of biotechnology and pharmaceuticals. Annalisa started their career as a Research Fellow at the University of Siena in 2006 and then joined Novartis Vaccines and Diagnostics in 2007 as a PhD student. During their PhD, they focused on applying the structural vaccinology approach to develop new vaccine candidates for Group B Streptococcus infections. Annalisa also carried out postdoctoral research at Novartis, contributing to the structural and functional characterization of proteins involved in pilus assembly.

In 2011, Annalisa had a brief Postdoc experience at Technische Universität München before joining F-star in 2012 as a Postdoctoral Research Associate/Scientist. In this role, they worked on research projects related to antibody engineering.

In 2013, Annalisa joined MedImmune as an Antibody Engineer/AAV Scientist. Their work at MedImmune focused on utilizing and developing display technologies to generate scFV antibodies for therapeutic use. Annalisa also used structural biology tools to guide library generation and lead optimization campaigns.

Annalisa then moved to AstraZeneca in 2019, where they served as an AAV Senior Scientist. In this role, they worked on AAV-related projects before joining Mogrify in 2022 as an AAV Principal Scientist.

Currently, Annalisa is employed at Mestag Therapeutics starting from June 2023, where they hold the position of Antibody Discovery Principal Scientist/Team Leader.

Annalisa Nuccitelli's education history includes their time as a Research Fellow at Università degli Studi di Siena from 2006 to 2007. Prior to that, they pursued a degree in Pharmaceuticals Biothecnology at Alma Mater Studiorum – Università di Bologna, completing their studies from 2001 to 2006.